314 related articles for article (PubMed ID: 26637771)
41. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
42. Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no... well yes, ...but maybe not for long.
Moskowitz AJ; Lunning MA; Horwitz SM
Cancer J; 2012; 18(5):445-9. PubMed ID: 23006950
[TBL] [Abstract][Full Text] [Related]
43. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers.
Niitsu N; Hayama M; Yoshino T; Nakamura S; Tamaru J; Nakamine H; Okamoto M
Br J Haematol; 2011 Jun; 153(5):582-8. PubMed ID: 21492124
[TBL] [Abstract][Full Text] [Related]
44. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
45. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
46. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Kawamoto K; Suzuki T; Kasami T; Kiryu M; Sone H; Miyoshi H; Ohshima K; Takizawa J
Hematol Oncol; 2019 Apr; 37(2):212-214. PubMed ID: 30394560
[No Abstract] [Full Text] [Related]
47. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A; Soma L
Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
[TBL] [Abstract][Full Text] [Related]
48. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
[TBL] [Abstract][Full Text] [Related]
49. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
[TBL] [Abstract][Full Text] [Related]
50. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S; O'Connor OA; Pro B; Trümper L; Iyer S; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Menne T; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Zinzani PL; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Illidge T
Ann Oncol; 2022 Mar; 33(3):288-298. PubMed ID: 34921960
[TBL] [Abstract][Full Text] [Related]
51. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
52. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
Ludvigsen Al-Mashhadi A; Cederleuf H; Kuhr Jensen R; Holm Nielsen T; Bjerregård Pedersen M; Bech Mortensen T; Relander T; Jerkeman M; Ortved Gang A; Kristensen AL; Roost Clausen M; de Nully Brown P; Tang Severinsen M; Jakobsen LH; Ellin F; El-Galaly TC
Am J Hematol; 2023 Mar; 98(3):388-397. PubMed ID: 36588403
[TBL] [Abstract][Full Text] [Related]
53. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
[TBL] [Abstract][Full Text] [Related]
54. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
55. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
[TBL] [Abstract][Full Text] [Related]
56. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
Ellin F; Landström J; Jerkeman M; Relander T
Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
[TBL] [Abstract][Full Text] [Related]
57. The aggressive peripheral T-cell lymphomas: 2013.
Armitage JO
Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
[TBL] [Abstract][Full Text] [Related]
58. Development of new agents for peripheral T-cell lymphoma.
Ito Y; Makita S; Tobinai K
Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
[TBL] [Abstract][Full Text] [Related]
59. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Yang Y; Sievers EL; Kennedy DA; Shustov A
J Clin Oncol; 2012 Jun; 30(18):2190-6. PubMed ID: 22614995
[TBL] [Abstract][Full Text] [Related]
60. First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature.
Chernova NG; Zvonkov EE; Badmazhapova DS; Sinitsyna MN; Grebenyuk LA; Sidorova YV; Kostina IE; Kovrigina AM; Obukhova TN; Sudarikov AB; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):77-81. PubMed ID: 30701926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
